IPG-GALANTAMINE ER CAPSULE (EXTENDED RELEASE)

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

GALANTAMINE (GALANTAMINE HYDROBROMIDE)

Pieejams no:

MARCAN PHARMACEUTICALS INC

ATĶ kods:

N06DA04

SNN (starptautisko nepatentēto nosaukumu):

GALANTAMINE

Deva:

8MG

Zāļu forma:

CAPSULE (EXTENDED RELEASE)

Kompozīcija:

GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

10

Receptes veids:

Prescription

Ārstniecības joma:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0144660002; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2016-09-07

Produkta apraksts

1
PRODUCT MONOGRAPH
PR
IPG-GALANTAMINE ER
galantamine hydrobromide extended release capsules
8 mg, 16 mg, 24 mg galantamine base
Cholinesterase Inhibitor
Marcan Pharmaceuticals Inc.
Date of Revision:
77 Auriga Drive, Unit# 4
November 27, 2017
Ottawa, ON, CANADA
K2E 7Z7
Control No.: 210932
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
.................................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................................
3
CONTRAINDICATIONS
............................................................................................................................
3
WARNINGS AND PRECAUTIONS
..........................................................................................................
3
ADVERSE REACTIONS
............................................................................................................................
7
DRUG INTERACTIONS
...........................................................................................................................
12
DOSAGE AND ADMINISTRATION
......................................................................................................
14
OVERDOSAGE
.........................................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................................
16
STORAGE AND STABILITY
..................................................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................................
20
PART II: SCIENTIFIC INFORMATION
.............................................................................................